PRTM

Carbon Revolution Appoints Chris Recktenwald to Lead Strategic Procurement and Supply Chain

Retrieved on: 
Thursday, February 8, 2024

GEELONG, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Carbon Revolution plc (Nasdaq: CREV) (the “Company”), a Tier 1 OEM supplier and the leading global manufacturer of lightweight advanced technology carbon fiber automotive wheels, today announced the appointment of Chris Recktenwald as Vice President, Procurement and Supply Chain, to lead strategic procurement and supply chain initiatives for Carbon Revolution globally.

Key Points: 
  • GEELONG, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Carbon Revolution plc (Nasdaq: CREV) (the “Company”), a Tier 1 OEM supplier and the leading global manufacturer of lightweight advanced technology carbon fiber automotive wheels, today announced the appointment of Chris Recktenwald as Vice President, Procurement and Supply Chain, to lead strategic procurement and supply chain initiatives for Carbon Revolution globally.
  • Before joining Carbon Revolution, Recktenwald held multiple senior positions over his 10 years at Ford Motor Company, including, most recently, Global Director, Exterior and Structural Systems Purchasing.
  • Recktenwald also brings experience as the head of Purchasing and Supplier Quality for Ford of Mexico, where he was instrumental in establishing supply chain networks and purchasing organizations.
  • “Chris will play a critical leading role as we look to further expand our growing footprint among global auto OEMs,” said Jake Dingle, CEO of Carbon Revolution.

Neuron23 Appoints Andrew Yost, MBA, as Chief Business Officer

Retrieved on: 
Tuesday, August 22, 2023

SOUTH SAN FRANCISCO, Calif., Aug. 22, 2023 /PRNewswire/ -- Neuron23™ Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced the appointment of Andrew Yost, MBA, as the company's chief business officer (CBO). Mr. Yost will be responsible for overseeing Neuron23's corporate strategy, strategic partnerships and collaborations, and licensing activities.

Key Points: 
  • Senior industry leader brings substantial strategy, business development, and operations experience
    SOUTH SAN FRANCISCO, Calif., Aug. 22, 2023 /PRNewswire/ -- Neuron23™ Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced the appointment of Andrew Yost, MBA, as the company's chief business officer (CBO).
  • "Andrew's deep understanding of the biotechnology business, coupled with his substantial experience in business development, strategic planning, and operations, will serve Neuron23 well in our next phase of corporate development," said Nancy Stagliano, Ph.D., chief executive officer of Neuron23.
  • Mr. Yost has nearly two decades of experience in strategy and business development and is well-versed in therapeutics development, strategic transactions, operations, and finance.
  • Before joining Neuron23, he served as CBO at TenSixteen Bio, where he oversaw the precision medicine company's business development, finance, legal, and operations functions.

GBW Attorneys Obtain Groundbreaking $39 Million Jury Verdict Against the Regents of The University of California for Doctor's Whistleblower Retaliation

Retrieved on: 
Monday, August 14, 2023

The jury unequivocally supported Dr. Kevin Murphy in his retaliation case against the UC Regents in San Diego Superior Court.

Key Points: 
  • The jury unequivocally supported Dr. Kevin Murphy in his retaliation case against the UC Regents in San Diego Superior Court.
  • Dr. Murphy, age 55, contended that the university diverted these funds to the Moores Cancer Center without obtaining his consent.
  • When he acted as a whistleblower to expose this wrongdoing, he faced severe backlash and ultimately lost his job.
  • The Regents of The University of California
    View original content to download multimedia: https://www.prnewswire.com/news-releases/gbw-attorneys-obtain-groundbrea...
    SOURCE Greene Broillet & Wheeler, LLP

Vince Zosa Joins Stax as Managing Director in Boston

Retrieved on: 
Tuesday, November 29, 2022

Zosa joins Stax from Treacy & Company and brings more than 20 years of private equity and corporate advisory experience in driving profitable growth across a variety of industries.

Key Points: 
  • Zosa joins Stax from Treacy & Company and brings more than 20 years of private equity and corporate advisory experience in driving profitable growth across a variety of industries.
  • "With decades of advising private equity firms, portfolio companies, and publicly-traded entities at the top level, Vince's expertise perfectly aligns with Stax's client base, strategic vision, and data-driven insight," said Paul Edwards, Senior Managing Director, Stax.
  • Stax is poised for tremendous growth as a leader in analytically driven, results-centered consulting both within the PE space and beyond," said Vince Zosa.
  • Prior to Stax, Zosa was a Partner at Treacy & Company and previously in project leader roles at Bain & Company and PRTM/PwC.

Designing Future Decades for Veteran and Aspiring Publicists

Retrieved on: 
Thursday, September 22, 2022

DALLAS, Sept. 22, 2022 /PRNewswire/ -- Women in PR™ is pleased to announce the return of its in-person weekend summit. This year marks the tenth anniversary of the first summit, which was held in 2012 in Miami, Florida. The two-day summit will be held from November 3-6, 2022, at the Kimpton Pittman Hotel in Dallas, Texas, to commemorate this special return.

Key Points: 
  • This year marks the tenth anniversary of the first summit, which was held in 2012 in Miami, Florida.
  • The two-day summit will be held from November 3-6, 2022, at the Kimpton Pittman Hotel in Dallas, Texas, to commemorate this special return.
  • The weekend summit will feature keynote speakers and panelists from the industry, as well as specialized breakout sessions and workshops to help new and veteran publicists expand their capabilities.
  • Anje Collins, a 36-year veteran entertainment publicist, co-founded the Women In PR Summit.

AnaptysBio Appoints Daniel Faga As Interim Chief Executive Officer

Retrieved on: 
Monday, March 21, 2022

SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced the appointment of Daniel Faga as interim president and chief executive officer (CEO), effective immediately.

Key Points: 
  • SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced the appointment of Daniel Faga as interim president and chief executive officer (CEO), effective immediately.
  • He is a seasoned executive with more than 20 years of industry and advisory experience in the life sciences industry.
  • Most recently, he was the chief operating officer at Mirati Therapeutics responsible for leading the companys strategy, corporate finance, legal and other business operations.
  • Prior to Mirati, Dan was chief business officer at Spark Therapeutics until its acquisition by Roche.

Outcome Capital Expands Its HealthTech and Digital Health Practice with the Addition of Karl Hess as Managing Director

Retrieved on: 
Monday, March 28, 2022

Outcome Capital, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that Karl Hess has been appointed as Managing Director in its Boston office.

Key Points: 
  • Outcome Capital, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that Karl Hess has been appointed as Managing Director in its Boston office.
  • Mr. Hess will lead the firms HealthTech and Digital Health segment, a rapidly growing practice area that is benefiting from Outcomes 20+-year track record of successful transactions and managed transformation opportunities for its life sciences clients.
  • His work has spanned the digital health continuum, including medical devices, software (SaMD), digital health tools and therapeutics, health optimization, and population health management platforms.
  • Mr. Hess was most recently Interim President and CEO of Texas Health Aetna, a health innovation company created by Texas Health Resources and Aetna, a CVS Health Company.

Netreo Appoints Melissa Phillips as VP of Product Management

Retrieved on: 
Wednesday, January 19, 2022

Phillips takes on responsibility of Netreos product management team in the ongoing development of the companys suite of monitoring and observability solutions: Netreo full-stack IT infrastructure management, Retrace full lifecycle APM, and Prefix real-time code profiling.

Key Points: 
  • Phillips takes on responsibility of Netreos product management team in the ongoing development of the companys suite of monitoring and observability solutions: Netreo full-stack IT infrastructure management, Retrace full lifecycle APM, and Prefix real-time code profiling.
  • Melissa has strategic leadership and practical, hands-on experience in technology product development, business management, and operations across diverse industries that align well with our existing customer base and target markets, said Netreo co-founder and president Andrew Anderson.
  • Were looking forward to her strategic insights and contributions to product management and operations.
  • A deep understanding of the customer, their priorities and pressures is key to developing the right products and services, said Melissa Phillips.

Netreo Adds Aritomo “Ari” Shinozaki as New VP Engineering

Retrieved on: 
Tuesday, November 30, 2021

Huntington Beach, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Netreo, the award-winning provider of IT infrastructure and application performance management solutions, today announced the appointment of Aritomo Ari Shinozaki as the new vice president of engineering.

Key Points: 
  • Huntington Beach, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Netreo, the award-winning provider of IT infrastructure and application performance management solutions, today announced the appointment of Aritomo Ari Shinozaki as the new vice president of engineering.
  • A 30-year technology industry veteran, management consultant and entrepreneur, Shinozaki brings extensive technology strategy, innovation, and operational expertise to Netreos executive leadership and engineering teams.
  • He takes over responsibility of Netreos engineering and quality assurance departments and the successful development and implementation of new technologies.
  • We are delighted to have top industry talent help shape the future of Netreo through innovative technology development, said Netreo President, Andrew Anderson.

AnaptysBio Announces Appointment of Daniel Faga to Board of Directors

Retrieved on: 
Monday, November 29, 2021

SAN DIEGO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced the appointment of Mr. Daniel Faga to the companys Board of Directors.

Key Points: 
  • SAN DIEGO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced the appointment of Mr. Daniel Faga to the companys Board of Directors.
  • His unique strategic vision is an exciting addition to our Board of Directors and we look forward to having Dans perspective as AnaptysBio continues to advance multiple wholly-owned clinical and preclinical first-in-class therapeutic antibody programs.
  • Mr. Faga commented, AnaptysBio has an impressive track-record of innovating novel therapeutics and is financially well-positioned to drive potentially transformative medicines over the next several years.
  • AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation.